|
業務類別
|
-- |
|
業務概覽
|
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States. |
| 公司地址
| 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015 |
| 電話號碼
| +61 292094037 |
| 傳真號碼
| +61 292094037 |
| 公司網頁
| https://www.claritypharmaceuticals.com |
| 員工數量
| -- |
| Dr. Colin Biggin, PhD |
Director and Chief Operating Officer |
-- |
05/09/2025 |
| Ms. Michelle Parker |
Director, Managing Director and Chief Executive Officer |
-- |
05/09/2025 |
|
|
| Dr. Alan Taylor, PhD |
Executive Chairperson of the Board |
05/09/2025 |
| Dr. Colin Biggin, PhD |
Director and Chief Operating Officer |
05/09/2025 |
| Ms. Rosanne Robinson |
Lead Independent Director |
05/09/2025 |
| Dr. Christopher G. Roberts,PhD |
Independent Director |
05/09/2025 |
| Ms. Michelle Parker |
Director, Managing Director and Chief Executive Officer |
05/09/2025 |
| Dr. Thomas Ramdahl |
Independent Director |
05/09/2025 |
|
|
|
|
